We could arguably put this phase 1 trial down as a phase 2...It's increasingly looking that way.
It's an expanded phase 1 trial, keep this in mind.
It's also targeting a rare and unmet need in TCL cancers.
So when you have these levels of efficacy, in a expanded trial targeting these types of cancer...That's got blanket orphan status from FDA...I think we can confidently say next stop is registrational trial, skipping phase 2.
This means a massive saving in the tens of millions on a phase 2 trial.
This also likely means a much much smaller registrational trial than tradition...Due to it being unmet need of TCL...Likely a further saving in the tens of millions.
So we could have a drug that's quickly fast tracked to market by the FDA...This story could move at a rapid rate of knots.
Another important consideration...Not only is PTX-100 targeting an unmet need...But even if that need were suddenly met by competitors eg. A CAR-T program...It must be remembered that current CAR-T therapies are often $500k per dose...PTX-100 wouldn't come close and could be a very cost effective option for oncologist and patients without the deep pockets for more expensive options...The future looks very promising indeed.
- Forums
- ASX - By Stock
- PTX
- Ann: Continued promising results in PTX-100 TCL trial
Ann: Continued promising results in PTX-100 TCL trial, page-38
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $33.01M |
Open | High | Low | Value | Volume |
4.0¢ | 4.1¢ | 4.0¢ | $21.95K | 548.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 28166 | 4.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.1¢ | 224042 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 28166 | 0.040 |
8 | 634751 | 0.039 |
5 | 1170000 | 0.038 |
8 | 396864 | 0.037 |
2 | 575000 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.041 | 224042 | 2 |
0.042 | 570000 | 3 |
0.043 | 421000 | 2 |
0.045 | 278101 | 4 |
0.046 | 39540 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online